(Reuters) -MeiraGTx Holdings has signed a deal with Eli Lilly, potentially worth over $475 million, granting the pharma giant ...

Lilly will also gain certain rights to MeiraGTx’s proprietary riboswitch technology for use in gene editing in the eye. Under ...

Eli Lilly has penned a research pact worth $1.2 billion in biobucks with SanegeneBio to help pinpoint cardiometabolic RNAi ...

Eli Lilly shares are rising Monday after Leerink Partners upgraded the stock to Outperform and raised its price target to ...

Eli Lilly is partnering with MeiraGTx to develop and commercialize ophthalmology gene therapies, and with SanegeneBio to ...

Eli Lilly's next generation of weight loss drugs appear to show promise, possibly leading to even faster weight loss and ...

Eli Lilly will partner with Insilico Medicine on an artificial intelligence (AI)-based drug development collaboration that they said could generate “over $100 million” for the AI drug discovery ...

For long-term investors, there are plenty of reasons to buy and hold Eli Lilly for not only years but decades.

The Trump administration on Thursday rolled out a much-anticipated deal with drugmakers Eli Lilly and Novo Nordisk that aims ...

In the preceding three months, 12 analysts have released ratings for Eli Lilly (NYSE: LLY ), presenting a wide array of perspectives from bullish to bearish. The following table summarizes their ...

Eli Lilly Strikes a Landmark Pricing Deal With the U.S. for Its Billion-Dollar Weight Loss Drugs. Here's What This Means for ...

The prices of Ozempic and Wegovy will fall from $1,000 and $1,350 per month, respectively, to $350 when purchased through ...